Department of Gastrointestinal Surgery, Xiangya Hospital, Central South University, 410008, PR China.
Life Sci. 2013 May 20;92(17-19):896-902. doi: 10.1016/j.lfs.2013.03.010. Epub 2013 Apr 3.
The EZH2 gene, which is expressed in various solid tumours, including liver cancer, can regulate gene transcription and promote the generation and progression of tumours. Our aim was to investigate the relationship between EZH2 and multidrug-resistance of human hepatic cancer cells using RNA interference.
We detected the expression of EZH2 in the human hepatic multidrug-resistant cancer cell line Bel/Fu by RT-PCR and western blot; then knocked EZH2 gene by RNA interference to investigate the proliferation, the cell cycle and cell apoptosis by MTT and flow cytometry; finally we checked the alteration of MDR1 methylation and MDR1 expression after EZH2 silencing by MS-PCR, RT-PCR and western blot.
EZH2 is highly expressed in Bel/Fu cells. After EZH2-depleted Bel/Fu cells were treated with 5-Fu, the cell proliferation was inhibited, the cell cycle arrested at G1, which may be associated with the alteration of G1/S checkpoint regulators, meanwhile the apoptotic rate of the cells increased. Furthermore, the expression of MDR1 decreased and the corresponding methylation levels of MDR1 were significantly increased in EZH2-depleted Bel/Fu cells.
We demonstrate the relationship between EZH2 and multidrug-resistance in hepatic cancer for the first time. EZH2 may become a new target for gene therapy to reverse multidrug-resistance in hepatic cancer.
EZH2 基因在包括肝癌在内的各种实体瘤中表达,可调节基因转录,促进肿瘤的发生和进展。本研究旨在采用 RNA 干扰技术探讨 EZH2 与肝癌细胞多药耐药的关系。
采用 RT-PCR 和 Western blot 检测人肝癌多药耐药细胞系 Bel/Fu 中 EZH2 的表达;用 RNA 干扰技术敲低 EZH2 基因,通过 MTT 及流式细胞术检测细胞增殖、细胞周期及细胞凋亡;最后采用 MS-PCR、RT-PCR 和 Western blot 检测 EZH2 沉默后 MDR1 甲基化和 MDR1 表达的改变。
EZH2 在 Bel/Fu 细胞中高表达。经 EZH2 耗竭的 Bel/Fu 细胞用 5-Fu 处理后,细胞增殖受到抑制,细胞周期阻滞在 G1 期,这可能与 G1/S 检查点调控因子的改变有关,同时细胞凋亡率增加。此外,EZH2 耗竭的 Bel/Fu 细胞中 MDR1 的表达降低,相应的 MDR1 甲基化水平显著升高。
本研究首次证实了 EZH2 与肝癌多药耐药之间的关系。EZH2 可能成为逆转肝癌多药耐药的基因治疗的新靶点。